Biguanide mechanism discovered

Researchers have discovered a novel mechanism by which biguanides exert their glucose-lowering effect, potentially leading to new therapeutic approaches to the treatment of diabetes and insulin resistance.

"We have shown that it is through an elevation in intracellular AMP [adenosine monophosphate] that metformin substantially abrogates the activation of adenylate cyclase by glucagon. This results in a reduction in the phosphorylation of key substrates for maintaining hepatic glucose output," report Morris Birnbaum (University of Pennsylvania, Philadelphia, USA) and colleagues.

Some experts previously believed that metformin reduces glucose synthesis through activation of AMP-activated protein kinase (AMPK), but this has recently been challenged by studies showing that mice without AMPK still respond to metformin, explain the authors.

In primary mouse hepatocytes, the team found that 24-hour exposure to phenformin at concentrations of 10 µM or greater significantly reduced glucagon-stimulated increases in cyclic AMP (cAMP) levels. Similarly, exposure to metformin at 125 µM also inhibited cAMP accumulation.

Exposure to each of the drugs also resulted in significant increases in intracellular levels of AMP.

The team explains that under usual circumstances, the binding of glucagon to its receptor on hepatocyte membranes activates the enzyme adenylate cyclase, which stimulates the synthesis of cyclic AMP (cAMP) from adenosine triphosphate (ATP) and the activity of protein kinase. Protein kinase activity (PKA) results in the phosphorylation of protein targets, which then work together to increase hepatic glucose output.

However, as metformin and phenformin blocked glucagon-induced cAMP production at concentrations that correlated well with their effects on AMP levels, the authors tested whether AMP could directly inhibit adenylate cyclase.

As reported in Nature, AMP inhibited glucagon-stimulated adenylate cyclase activity when ATP was present at 160 µM (typical assay conditions) as well as at the more physiological ATP concentration of 1.28 mM.

Furthermore, in mice injected with metformin, the glucagon-dependent increases in hepatic cAMP were reduced, as were PKA and the phosphorylation of PKA substrates, demonstrating the in vivo blockade of this pathway by the biguanides, says the team.

"Understanding the mechanism by which the drug metformin reduces hepatic glucose is of considerable importance," write Birnbaum et al.

The findings suggest that adenylate cyclase might represent a novel target for the development of treatments for insulin resistance and Type 2 diabetes, they conclude.

Licensed from medwireNews with permission from Springer Healthcare Ltd. ©Springer Healthcare Ltd. All rights reserved. Neither of these parties endorse or recommend any commercial products, services, or equipment.

Sally Robertson

Written by

Sally Robertson

Sally has a Bachelor's Degree in Biomedical Sciences (B.Sc.). She is a specialist in reviewing and summarising the latest findings across all areas of medicine covered in major, high-impact, world-leading international medical journals, international press conferences and bulletins from governmental agencies and regulatory bodies. At News-Medical, Sally generates daily news features, life science articles and interview coverage.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Robertson, Sally. (2018, August 23). Biguanide mechanism discovered. News-Medical. Retrieved on October 24, 2020 from https://www.news-medical.net/news/20130114/Biguanide-mechanism-discovered.aspx.

  • MLA

    Robertson, Sally. "Biguanide mechanism discovered". News-Medical. 24 October 2020. <https://www.news-medical.net/news/20130114/Biguanide-mechanism-discovered.aspx>.

  • Chicago

    Robertson, Sally. "Biguanide mechanism discovered". News-Medical. https://www.news-medical.net/news/20130114/Biguanide-mechanism-discovered.aspx. (accessed October 24, 2020).

  • Harvard

    Robertson, Sally. 2018. Biguanide mechanism discovered. News-Medical, viewed 24 October 2020, https://www.news-medical.net/news/20130114/Biguanide-mechanism-discovered.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
GIV protein involved in the immune system could form basis for novel therapeutics